Summary:
In patients with clinically significant macular edema (CSME) in type 2 diabetes mellitus,
low-dose atorvastatin (10-20 mg) significantly improved functional and anatomical outcomes
compared to high-dose atorvastatin, though it was associated with minimal side effects.
| PICO | Description |
|---|---|
| Population | Patients with clinically significant macular edema (CSME) secondary to type 2 diabetes mellitus. |
| Intervention | Low-dose atorvastatin (10-20 mg) as adjunctive therapy to anti-VEGF treatment. |
| Comparison | High-dose atorvastatin (40-80 mg) used alongside anti-VEGF therapy. |
| Outcome | Low-dose atorvastatin significantly improved functional (e.g., visual acuity) and anatomical outcomes (e.g., retinal thickness) compared to high-dose treatment. Minimal side effects were reported for low-dose use. |
Source: Ashish Markan, et al. “Assessing the Role of Statins as an Adjunctive Anti-VEGF Therapy for Clinically Significant Macular Edema (CSME) in Type 2 Diabetes Mellitus.” Read article here.
